Increasing the potential of TMC207/R207910

Thursday, August 27th, 2009 by hinrich

Structure of TMC207/R207910

Tibotec and the Global Alliance for TB Drug Development (TB Alliance) have announced in June that they will jointly work on the development of TMC207/R207910.

While Tibotec will focus on developing the compound for multidrug-resistant TB (MDR-TB), the Global Alliance for TB Drug Development (TB Alliance) will attempt to develop the compound for drug-susceptible TB. The hope is that these two parallel programs will be able to benefit from one another.

Making use of TMC207/R207910 for the treatment of drug-susceptible TB could potentially lead to shorter treatment protocols which in turn could prove beneficial in the fight against MDR-TB as patients who do not complete the treatment of drug-susceptible TB increase their likelihood of developing drug resistance. Currently more than 5% of deaths caused by TB are linked to MDR-TB.

Some more information can be found in a recently published article in Nature Reviews Drug Discovery.

Posted in Tuberculosis


Categories

Archives